WhatsApp：+447349736496
Telegram:+8618049650067

Product Information

I. Basic Properties & Mechanism of Action

CagriSema is a fixed-dose combination therapy consisting of an amylin analog (cagrilintide) and a GLP-1 receptor agonist (semaglutide), administered via once-weekly subcutaneous injection. Its dual-pathway design integrates complementary metabolic regulation mechanisms:

• Cagrilintide: Activates amylin and calcitonin receptors (AMYR/CTR), suppressing appetite and delaying gastric emptying.

• Semaglutide: Enhances insulin secretion, inhibits glucagon release, and synergistically modulates feeding behavior.
  The components demonstrate cooperative action for dual control of energy intake and glucose metabolism .

II. Clinical Research Findings

1. Weight Management

• Non-diabetic population (REDEFINE-1, n=3,417):
  20.4% mean weight reduction after 68 weeks; 53.6% of participants achieved ≥20% weight loss. Fully adherent subgroup reached 22.7% reduction.

• Type 2 diabetes population (REDEFINE-2, n=1,206):
  13.7% mean weight loss; 73.5% achieved glycemic target (HbA1c ≤6.5%).

2. Metabolic Improvements

• Glycemic control: HbA1c reduction of 2.18% from baseline, significantly exceeding monotherapy outcomes.

• Additional benefits: Concurrent improvements in blood pressure, lipid profiles, and insulin sensitivity.

Efficacy Comparison (68-week data)

1. 1. • III. Safety & Tolerability

        • Primary adverse events: Mild-to-moderate gastrointestinal incidents (nausea, vomiting, diarrhea; ~72.5% incidence), predominantly during dose escalation and typically transient.

        • No new safety signals: No clinically significant cardiovascular or neuropsychiatric adverse events observed in trials.

        • Dosing flexibility: Dynamic dose adjustment permitted, with lowest discontinuation rate in class (<5%).

        ---

        IV. Development Status & Research Directions

        1. Indication focus:

           • Core targets: Obesity (BMI≥30) and type 2 diabetes with obesity.

           • Long-term cardiometabolic outcome studies (REDEFINE 3/4) expected 2025.

        2. Competitive assessment:

           • Active head-to-head Phase III trial vs. tirzepatide (n=800; results 2025).

        3. Formulation optimization:

           • Exploring oral (e.g., Amycretin) and monthly injectable formulations to improve adherence.

         

Company Introduction

csxj Technology Co., Ltd. is an innovative technology enterprise specializing in the field of weight management and metabolic health. We are dedicated to the R&D, production, and supply of high-quality solutions based on cutting-edge biotechnology for the global market, with core expertise in GLP-1-related products and high-purity active ingredients. Leveraging robust scientific capabilities and a stringent quality management system, we consistently deliver safe, efficient weight management and metabolic products and materials to meet diverse client needs. Driven by technological innovation and a customer-centric approach, we collaborate with partners to advance the health industry and empower global users in achieving healthier lifestyles.

Introduction to transportation
We usually use a safe shipping method and do not require you to go through any customs clearance. Free shipping to your address without worrying about any customs issues. We have a professional customs clearance team that 100% guarantees the safe delivery of your package. If anything happens to your package, we promise to send it again for free. Enjoy the second free reissue policy. We can safely ship large parcels of 1000-2000kg/time without any customs issues. Our mission is always to put safety first.

Product Certificates